Cutler Group LP Cellectis S.A. Call Options Transaction History

Cutler Group LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Jan 18, 2024	BUY	$0.97 - $3.55 $679 - $2,485	700 New	700 $0
Q1 2018 May 11, 2018	SELL	$27.78 - $35.19 $161,124 - $204,102	-5,800 Reduced 95.08%	300 $0
Q4 2017 Jan 17, 2018	SELL	$23.33 - $35.01 $72,323 - $108,531	-3,100 Reduced 33.7%	6,100 $12,000
Q3 2017 Oct 17, 2017	BUY	$21.65 - $32.18 $199,180 - $296,056	9,200	9,200 $10,000

11.2M

2.8K

17.9K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $82.8M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.